Clinical Trial Update: A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL) [Phase 1]

View source ↗

Summary

A Phase 1 study of JNJ-80948543, a T-cell redirecting trispecific antibody, in Non-Hodgkin lymphoma and chronic lymphocytic leukemia, is currently active but no…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Non-hodgkin Lymphoma

Drugs mentioned

• JNJ-80948543 (JNJ-80948543)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell | Phase 1 | Status: ACTIVE_NOT_RECRUITING